Osteoprotegerin is expressed in colon carcinoma cells

Anticancer Research

Volumn 25, Issue 6 B, 2005, Pages 3809-3816

  Pettersen, Ingvild ^a   Bakkelund, Wenche ^a   Smedsrød, Bård ^a   Sveinbjørnsson, Baldur ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Colon cancer; IL 1 ; Immunohistochemistry; Osteoprotegerin; RANKL; TNF

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT INTERLEUKIN 1BETA; RECOMBINANT PROTEIN; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; RNA;

APOPTOSIS; ARTICLE; CANCER CELL; COLON CARCINOGENESIS; COLON CARCINOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CARRIER PROTEINS; CELL LINE, TUMOR; COLONIC NEOPLASMS; GLYCOPROTEINS; HT29 CELLS; HUMANS; INTERLEUKIN-1; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 27944448767     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Lacey, DL, Timms E, Tan H-L, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian Y-X, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J and Boyle WJ: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998.
2. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM and Choi Y: TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 186: 2075-2080, 1997.
3. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997.
4. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N and Suda T: Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95: 3597-35602, 1998.
5. Kostenuik PJ and Shalhoub V: Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr Pharmaceut Design 7: 613-635, 2001.
6. Bengtsson AK and Ryan EJ: Immune function of the decoy receptor osteoprotegerin. Crit Rev Immunol 22: 201-215, 2002.
7. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, Steinman RM and Choi Y: TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191: 495-502, 2000.
8. Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A and Choi Y: TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation, J Exp Med 189: 1025-1031, 1999.
9. Ashcroft AJ, Cruickshank SM, Croucher PI, Perry MJ, Rollinson S, Lippitt JM, Child JA, Dunstan C, Felsburg PJ, Morgan GJ and Carding SR: Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity 19: 849-861, 2003.
10. Emery JG, McDonnel P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC and Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 14363-14367, 1998.
11. Bonavida B, Ng CP, Jazirehi A, Schiller G and Mizutani Y: Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int J Oncol 15: 793-802, 1999.
12. Holen I, Croucher PI, Hamdy FC and Eaton CL: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells, Cancer Res 62: 1619-1623, 2002.
13. Shipman CM and Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63: 912-916, 2003.
14. Zhang XD, Franco A, Myers K, Gray C, Nguyen T and Hersey P: Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753, 1999.
15. Brown JM, Corey E, Lee ZD, True LD, Yun TJ, Tondravi M and Vessella RL: Osteoprotegerin and Rank ligand expression in prostate cancer. Urology 57: 611-616, 2001.
16. Penno H, Silferswärd CJ, Frost A, Brändström H, Nilsson O and Ljunggren Ö: Osteoprotegerin secretion from prostate cancer is stimulated by cytokines, in vitro. Biochem Biophys Res Commun 293: 451-455, 2002.
17. Evdokiou A, Bouralexis S, Atkins GJ, Chai F, Hay S, Clayer M and Findlay DM: Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to APO2L/TRAIL-induced apoptosis. Int J Cancer 99: 491-504, 2002.
18. Naumann U, Wick W, Beschorner R, Meyermann R and Weller M: Expression and functional activity of osteoprotegerin in human malignant gliomas. Acta Neuropathologica 107: 17-22, 2003.
19. Granchi D, Amato I, Battistelli L, Avnet S, Capaccioli S, Papucci L, Donnini M, Pellacani A, Brandi ML, Giunti A and Baldini N: In vitro blockade of receptor activator of nuclear factor-kappaB ligand prevents osteoclastogenesis induced by neuroblastoma cells. Int J Cancer 111: 829-838, 2004.
20. Ito R, Nakayama H, Yoshida K, Kuraoka K, Motoshita J, Oda N, Oue N and Yasui W: Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma, Virchows Arch 443: 146-151, 2003.
21. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63, 1983.
22. Huang L, Xu J, Wood DJ and Zheng MH: Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. Am J Pathol 156: 761-767, 2000.
23. Langaas V, Shahzidi S, Johnsen JI, Smedsrød B and Sveinbjørnsson B: Interferon-γ modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res 21: 3733-3738, 2001.
24. Feige U: Osteoprotegerin. Ann Rheum Dis Suppl 3: iii81-84, 2001.
25. Brown JM, Vessella RL, Kostenuik PJ, Dunstan CR, Lange PH and Corey E: Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7: 2977-2983, 2001.
26. Jung K, Lein M, von Hösslin K, Brux B, Schnorr D, Loening SA and Sinha P: Osteoprotegerin in serum is a novel marker of bone metastatic spread in prostate cancer. Clin Chem 47: 2061-2063, 2001.
27. Eaton CL, Wells JM, Holen I, Croucher PI and Hamdy FC: Serum osteoprotegerin (OPG) levels are assiciated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 59: 304-310, 2004.
28. Lipton A, Ali SM, Leitzel K, Chinchilli V, Witters L, Engle L, Holloway D, Bekker P, Dunstan CR: Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 8: 2306-2310, 2002.
29. Strater J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C, Moller P and Lehnert T: Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 12: 3734-3740, 2002.
30. Liao Q, Friess H, Kleff J and Büchler MW: Differential expression of TRAIL-R3 and TRAIL-R4 in human pancreatic cancer. Anticancer Res 21: 3153-3160, 2001.
31. Spierings DCJ, de Vries EGE, Timens W, Groen HJM, Boezen HM and de Jong S: Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 9: 3397-3405, 2003.
32. Hazra A, Chamberlain RM, Grossman B, Zhu Y, Spitz MR and Wu Xifeng: Death receptor 4 and bladder cancer risk. Cancer Res 63: 1157-1159, 2003.
33. Koornstra JJ, Kleibeuker JH, van Geelen CMM, Rijcken FEM, Hollema H, de Vries EGE and de Jong S: Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 362: 230-232, 2003.
34. Reesink-Peters N, Hougardy BM, van den Heuvel FA, Ten Hoor T, Hollema H, Boezen HM, de Vries EG, de Jong S and van der Zee AG: Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 96: 705-713, 2005.
35. Strater J, Walczak H, Pukrop T, Von Muller L, Hasel C, Kornmann M, Mertens T and Moller P: TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterol 122: 659-666, 2002.
36. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z and Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162, 1999.
37. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A and Shimosegawa T: Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. Pancreas 23: 251-258, 2001.
38. Brändstrøm H, Jonsson KB, Vidal O, Ljunghall S, Ohlsson C and Ljunggren Ø: Tumor necrosis factor-α and -β upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem Biophys Res Commun 248: 454-457, 1998.
39. Vidal ONA, Sjøgren K, Eriksson BI, Ljunggren Ø and Ohlsson C: Osteoprotegerin mRNA is increased by interleukin-1α in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem Biophys Res Commun 248: 696-700, 1998.
40. Pantouli E, Boehm MM and Koka S: Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. Biochem Biophys Res Commun 329: 224-229, 2005.
41. Brändström H, Björkman T and Ljunggren Ö: Regulation of OPG secretion from primary cultures of human bone marrow stromal cells. Biochem Biophys Res Commun 280: 831-835, 2001.
42. Collin-Osdoby P, Rothe L, Anderson F, Nelson M, Maloney W and Osdoby P: Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem 276: 20659-20672, 2001.
43. Hofbauer LC, Kluger S, Kuhne CA, Dunstan CR, Burchert A, Schoppet M, Zielke A and Heufelder AE: Detection and characterization of RANK ligand and osteoprotegerin in the thyroid gland. J Cell Biochem 86: 642-650, 2002.
44. Zhang J, Fu M, Myles D, Zhu X, Du J, Cao X and Chen YE: PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett 521: 180-184, 2002.
45. Olesen P, Ledet T and Rasmusen LM: Arterial osteoprotegerin: increased amounts in diabetes and modifiable synthesis from vascular smooth muscle cells by insulin and TNF-alpha. Diabetologia 48: 561-568, 2005.
46. Zannettino ACW, Holding CA, Diamond P, Atkins GJ, Kostakis P, Farrugia A, Gamble J, To LB, Findlay DM and Haynes DR: Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cellular Physiol 204: 714-723, 2005.
47. Takai H, Kanematsu M, Yano K, Tsuda E, Higashio K, Ikeda K, Watanabe K and Yamada Y: Transforming growth factor β stimulates the production of osteoprotegerin/osteoclastogenesis inhibitory factor by bone marrow stromal cells. J Biol Chem 273: 27091-27096, 1998.
48. Makiishi-Shimobayashi C, Tsujimura T, Iwasaki T, Yamada N, Sugihara A, Okamura, H, Hayashi S and Terada N: Interleukin-18 up-regulates osteoprotegerin expression in stromal/osteoblastic cells. Biochem Biophys Res Commun 281: 361-366, 2001.
49. Vidal K, Serrant P, Schlosser B, van den Broek P, Lorget F and Donnet-Hughes A: Osteoprotegerin production by human intestinal epithelial cells: a potent regulator of mucosal immune responses. Am J Physiol Gastrointest Liver Physiol 287: G836-G844, 2004.
50. Seljelid R, Jozefowski S and Sveinbjørnsson B: Tumor stroma review. Anticancer Res 19: 4809-4822, 1999.
51. Takeda K, Hayakawa Y, Smyth MJ, Kayagaki N, Yamaguchi N, Kakuta S, Iwakura Y, Yagita H and Okumura K: Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nature Med 7: 94-100, 2001.
52. Takeda K, Smyth MJ, Cretney E, Hayakawa Y, Kayagaki N, Yagita H and Okumura K: Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 195: 161-169, 2002.
53. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ and Smyth MJ: Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 168: 1356-1361, 2002.
54. Seki N, Hayakawa Y, Brooks AD, Wine J, Wiltrout RH, Yagita H, Tanner JE, Smyth MJ and Sayers TJ: Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 63: 207-213, 2003.
55. Cappello P, Novelli F, Forni G and Giovarelli M: Death receptor ligands in tumors. J Immunotherapy 25: 1-15, 2001.
56. Malyankar UM, Scatena M, Suchland KL, Yun TJ, Clark EA and Giachelli CM: Osteoprotegerin is an αvβ3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem 275: 20959-20962, 2000.
57. Scatena M and Giachelli C: The αvβ3 integrin, NF-κB, osteoprotegerin endothelial cell survival pathway. Potential role in angiogenesis. Trends Cardiovasc Med 12: 83-88, 2002.
58. Pritzker LB, Scatena M and Giachelli CM: The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell 15: 2834-2841, 2004.
59. Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ, Ewings ME, Mohaupt M, Herring SW and Clark EA: Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 166: 1482-1491, 2001.
60. Ra JS, Broxmeyer HE, Kim MW, Han I-S, Choi SW and Kwon BS: Osteoprotegerin inhibits proliferation of myeloid progenitor cells. J Hematother Stem Cell Res 12: 33-38, 2003.